# Lanboto

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lanboto

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.lanboto.com
- Total disclosed funding: $15M
- Latest round: Series C (Aug 29, 2024)
- Investors on record: 6

## About

Established in 2015 and based in Nanjing, China, Lanboto is a pet innovative drug developer that provides veterinary, pet specialties, food and feed. The company has a 2,000 square meter drug research and development center, 34 patents, and 8 new veterinary drug certificates. Chengqiang Zhu, the founder of the company, graduated from Nanjing Agricultural University, majoring in molecular genetics, and established Dr. Warm, a cloud-based SaaS management platform for pet hospitals. The company cooperates with Tmall Supermarket, Jingdong Self-support, Huayuan and Diman, etc. In August 2024, the company closed a series C funding from CICC Capital and Nanjing Jiangbei New Area Sci-Tech Investment Group.

The company has 7 veterinary GMP production lines, including eye drops, ear drops, topical ointments, tablets, oral solutions, non-chlorine disinfectants and topical insecticides. Its products are divided into two series, which include innovative pet drugs and generic drugs. Innovative pet drugs include compound glycyrrhizin tablets, compound amino acid injections, cefpodoxime tablets and fipronil solution. Generic drugs include compound mycophenolic ointment and fipronil drops. The company also provides online pet light consultation services and value-added services such as operations management empowerment.

The company generates revenue by selling compound glycyrrhizic acid tablets, pyrochloranil drops and other pet medicines.

## Funding rounds

- Series C, Aug 29, 2024 — China International Capital Corporation, Nanjing Jiangbei New Area Sci-Tech Investment Group
- Series B, Jul 13, 2023, $14M — Zhuopu Capital, InnoMed Capital
- Angel, Feb 28, 2019, $1.5M — Renai Capital, Xinchenxing Investment Management (Suzhou)

## Investors

- Renai Capital (https://capitalatlas.ai/funds/renai-capital) — Angel
- Xinchenxing Investment Management (Suzhou) — Angel
- Zhuopu Capital (https://capitalatlas.ai/funds/zhuopu-capital) — Series B
- InnoMed Capital (https://capitalatlas.ai/funds/innomed-capital) — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- Nanjing Jiangbei New Area Sci-Tech Investment Group — Series C